Recently, sirolimus, a rapamycin (mTOR) inhibitor, offers promising treatment results in patients with complex LMs.[12] Adverse effects are dose dependent and include hypertension, dyslipidemia, poor wound healing, bone marrow suppression (neutropenia, anemia, thrombocytopenia), and increased susceptibility to infections. This evidence concerns the gene MTOR and anemia.